Living the Life Pandemic

The first part of 2022 is giving us a glimpse of humanity’s future relationship with COVID-19.

Written byBob Grant
| 4 min read
Vector abstract world around coronavirus macro illustration.
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In late November 2021, The Scientist’s editorial team convened to discuss mounting case reports, coming mostly from South Africa, of patients infected with the newly described Omicron variant of SARS-CoV-2. We talked about this latest development in the COVID-19 pandemic, which we’ve been covering since before it was even called a pandemic, and how we might report on it. During that meeting, I expressed something to the effect of: “I wouldn’t be surprised if we’re not even talking about Omicron two weeks from now.” How wrong I turned out to be.

Here we are, well into a new year (the third of the COVID era), and the Omicron variant has washed over our pandemic-weary globe, adding to the case and body counts mounted by its viral predecessors. Hospitals around the world strained to treat COVID-19 patients in early 2022 while at the same time delivering much-needed, and in some cases ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Published In

Spring 2022 cover
Spring 2022

Cracking Cancer's Mysteries

Tumors’ unstable genomes and unique microbiomes may present new targets for understanding and treating the disease

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies